Spectranetics (SPNC) Announces CE Mark Approval for ThromCatXT
Up)
Spectranetics Corporation (Nasdaq: SPNC) received the CE mark approval for its next-generation ThromCat XT Thrombus Removal System, a single-use, disposable device indicated for mechanical removal of thrombus from native coronary arteries and infra-inguinal arteries.
The launch of the product will commence immediately within the European Union.
The approval triggers a milestone payment of $1.5 million pursuant to the Company's Amended Development and Regulatory Services agreement with Kensey Nash Corporation (Nasdaq: KNSY).
The launch of the product will commence immediately within the European Union.
The approval triggers a milestone payment of $1.5 million pursuant to the Company's Amended Development and Regulatory Services agreement with Kensey Nash Corporation (Nasdaq: KNSY).
You May Also Be Interested In
- Celldex (CLDX) volatility up into conference call to announce EMERGE results
- AVEO Oncology (AVEO) Commences AV-203 Phase 1 in Advanced Solid Tumors
- Amgen (AMGN) Updates on Exploratory Biomarker Analysis for AMG 102 Response Predictor
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
